Publikationen, an denen er mitarbeitet FRANCISCO VIVES MONTERO (112)

2023

  1. Asymmetric Pattern of Correlations of Leucine Aminopeptidase Activity between Left or Right Frontal Cortex versus Diverse Left or Right Regions of Rat Brains

    Symmetry, Vol. 15, Núm. 7

  2. Correlational Study of Aminopeptidase Activities between Left or Right Frontal Cortex versus the Hypothalamus, Pituitary, Adrenal Axis of Spontaneously Hypertensive Rats Treated with Hypotensive or Hypertensive Agents

    International Journal of Molecular Sciences, Vol. 24, Núm. 21

  3. Exploring the genetic and genomic connection underlying neurodegeneration with brain iron accumulation and the risk for Parkinson’s disease

    npj Parkinson's Disease, Vol. 9, Núm. 1

2022

  1. Aminopeptidase Activities Interact Asymmetrically between Brain, Plasma and Systolic Blood Pressure in Hypertensive Rats Unilaterally Depleted of Dopamine

    Biomedicines, Vol. 10, Núm. 10

  2. Asymmetric Interaction of Neuropeptidase Activities between Cortico-Limbic Structures, Plasma and Cardiovascular Function after Unilateral Dopamine Depletions of the Nigrostriatal System

    Biomedicines, Vol. 10, Núm. 2

  3. Phytochemical and Bioactivities of Male Flower Buds of Fruit Trees from the Southern Tunisia: Polyphenols UPLC-MS Profiles and Antioxidant Enzymatic Potential in Human Plasma of Parkinson's Disease Patients

    Chemistry Africa, Vol. 5, Núm. 5, pp. 1337-1350

  4. Saposin C, Key Regulator in the Alpha-Synuclein Degradation Mediated by Lysosome

    International Journal of Molecular Sciences, Vol. 23, Núm. 19

  5. Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line

    International Journal of Molecular Sciences, Vol. 23, Núm. 13

2021

  1. Evaluación de la contribución genética a la enfermedad de Parkinson.

    Encuentros en Neurociencias (Universidad de Granada), pp. 127-150

  2. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome

    Nature Communications, Vol. 12, Núm. 1

  3. Human-lineage-specific genomic elements are associated with neurodegenerative disease and APOE transcript usage

    Nature Communications, Vol. 12, Núm. 1

  4. Identification of sixteen novel candidate genes for late onset Parkinson’s disease

    Molecular Neurodegeneration, Vol. 16, Núm. 1

  5. Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease

    Annals of Neurology, Vol. 90, Núm. 1, pp. 35-42

  6. Saposina C en la Enfermedad de Parkinson: estructura y funciones.

    Encuentros en Neurociencias (Universidad de Granada), pp. 151-160

2020

  1. Dystonia genes functionally converge in specific neurons and share neurobiology with psychiatric disorders

    Brain, Vol. 143, Núm. 9, pp. 2771-2787

  2. Proteotoxicity and neurodegenerative diseases

    International Journal of Molecular Sciences, Vol. 21, Núm. 16, pp. 1-25

  3. Regulatory sites for splicing in human basal ganglia are enriched for disease-relevant information

    Nature Communications, Vol. 11, Núm. 1

2019

  1. Asymmetrical response of aminopeptidase A in the medial prefrontal cortex and striatum of 6-OHDA-unilaterally-lesioned Wistar Kyoto and spontaneously hypertensive rats

    Pharmacology Biochemistry and Behavior, Vol. 182, pp. 12-21

  2. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

    The Lancet Neurology, Vol. 18, Núm. 12, pp. 1091-1102

  3. Mitochondria function associated genes contribute to Parkinson’s Disease risk and later age at onset

    npj Parkinson's Disease, Vol. 5, Núm. 1